Progression of cardiotoxicity due to anti-HER-2 medication on patients with HER-2 positive breast cancer
ZENG Huagui
Abstract：Anti-human epidermal growth factor receptor-2(HER-2) therapies improved the prognosis of patients with HER-2 positive breast cancer.Trastuzumab, pertuzuma, lapatinib and T-DM1 are the major choices for these patients at present.Cardiotoxicity is one of the side effects of anti-HER-2 drugs and it puts patients at a risky position, which contains various manifestations and can be prevented and cured.Having knowledge of its symptoms, probabilities as well as its preventions and treatment helps to the process of anti-HER-2 treatment.
Keywords：Breast cancerHuman epidermal growth factor receptor-2(HER-2)Cardiotoxicity
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 362-368 )